Position in EXEL
as of Jun 30, 2026
· filed Jul 10, 2026
Position Value
$2,829
+$599 QoQ
Shares Held
52
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#159
of 180 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026DiNuzzo Private Wealth, Inc. holds $53,387 across 28 Biotechnology names. EXEL ranks #6 (5.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
27 | $13,411 | |
| 2 | TLSA |
Tiziana Life Sciences Ltd
|
5,000 | $6,400 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
6 | $3,741 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
13 | $3,132 | |
| 5 | INCY |
Incyte Corp
|
25 | $2,834 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
52 | $2,829 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
8 | $2,408 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
67 | $2,371 |
All Filings in EXEL
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,829 | 52 | Shares | Sole | 2026-07-10 | |
| 2026-03-31 | $2,230 | 52 | Shares | Sole | 2026-04-08 | |
| 2025-12-31 | $2,279 | 52 | Shares | Sole | 2026-01-16 | |
| 2025-09-30 | $2,354 | 57 | Shares | Sole | 2025-10-14 | |
| 2025-06-30 | $2,600 | 59 | Shares | Sole | 2025-07-17 | |
| 2025-03-31 | $1,882 | 51 | Shares | Sole | 2025-04-25 | |
| 2024-12-31 | $1,465 | 44 | Shares | Sole | 2025-01-23 | |
| 2024-09-30 | $1,141 | 44 | Shares | Sole | 2024-10-17 | |
| 2024-06-30 | $988 | 44 | Shares | Sole | 2024-07-30 | |
| 2024-03-31 | $901 | 38 | Shares | Sole | 2024-05-06 | |
| 2023-12-31 | $935 | 39 | Shares | Sole | 2024-05-06 | |
| No filing history on record for this holder in this stock. | ||||||